Table 2.
AST performance of AXDX compared with standard methodsa, following adjudication
| Antibiotic | EA | CA | VME | ME | S | I | R |
|---|---|---|---|---|---|---|---|
| Ampicillin/sulbactam | 84/93 (90.3%) | 74/93 (79.6%) | 0 | 1 | 47 | 14 | 32 |
| Piperacillin/tazobactam | 94/103 (91.3%) | 97/103 (94.2%) | 1 | 0 | 86 | 2 | 15 |
| Cefepime | 122/134 (91.0%) | 117/134 (87.3%) | 0 | 1 | 105 | 7 | 22 |
| Ceftazidime | 113/132 (85.6%) | 111/132 (84.1%) | 0 | 2 | 97 | 3 | 32 |
| Ceftriaxone | 115/115 (100%) | 113/115 (98.3%) | 0 | 0 | 81 | 1 | 33 |
| Meropenem | 123/128 (96.1%) | 123/128 (96.1%) | 0 | 2 | 114 | 0 | 14 |
| Amikacin | 125/127 (98.4%) | 126/127 (99.2%) | 0 | 0 | 121 | 1 | 5 |
| Gentamicin | 125/131 (95.4%) | 130/131 (99.2%) | 0 | 0 | 111 | 1 | 19 |
| Tobramycin | 126/131 (96.2%) | 125/131 (95.4%) | 0 | 0 | 108 | 7 | 16 |
| Ciprofloxacin | 131/132 (99.2%) | 130/132 (98.5%) | 0 | 0 | 93 | 1 | 38 |
| Aztreonam | 1/1 (100%) | 1/1 (100%) | 0 | 0 | 0 | 0 | 1 |
| Total | 1159/1227 (94.5%) | 1147/1227 (93.5%) | 1 | 6 | 963 | 37 | 227 |
a
VITEK® 2 (n=147) and Etest (n=2).